Characteristics | Total, n = 113 | Patients without Cytopenia, n = 86 | Patients with Cytopenia, n = 27 | p |
---|---|---|---|---|
Women | 112 (99.1) | 85 (98.8) | 27 (100) | > 0.999 |
Age, yrs | 55 (45–60) | 54 (45–60) | 57 (49–61) | 0.133 |
Disease duration, yrs | 1.6 (0.4–4.3) | 1.4 (0.3–4.5) | 3.2 (0.6–4.3) | 0.302 |
Xerostomia* | 111 (98.2) | 84 (97.7) | 27 (100) | > 0.999 |
Dry eye* | 112 (99.1) | 85 (98.8) | 27 (100) | > 0.999 |
OSS by SICCA method ≥ 3 | 71/101 (70.3) | 50/76 (65.8) | 21/25 (84.0) | 0.129 |
Schirmer I test ≤ 5 mm/5 min | 79/103 (76.7) | 56/79 (70.9) | 23/24 (95.8) | 0.012 |
Altered oral test† | 105 (92.9) | 80 (93.0) | 25 (92.6) | > 0.999 |
Positive salivary gland biopsy | 17/29 (58.6) | 16/27 (59.3) | 1/2 (50) | > 0.999 |
Anti-Ro/SSA-positive | 99/109 (90.8) | 74/84 (88.1) | 25/25 (100) | 0.112 |
Anti-La/SSB-positive | 58/109 (53.2) | 41/84 (48.8) | 17/25 (68.0) | 0.112 |
RF-positive | 77/110 (68.1) | 56/84 (65.1) | 21/26 (77.8) | 0.223 |
ANA ≥ 1:320 | 71/101 (70.3) | 51/75 (59.3) | 20/26 (74.1) | 0.462 |
ESSDAI | 2 (1–6) | 2 (0–5) | 6 (2.5–9.0) | < 0.001 |
ESSPRI | 5 (4.2–6) | 5.0 (4.0–6.0) | 5.3 (4.3–6.7) | 0.282 |
PtGA | 63 (48–78.5) | 61 (48–77) | 70 (48–81) | 0.443 |
SSDDI | 3 (2–3) | 3 (2–3) | 3 (2–4) | 0.093 |
EQ-5D | ||||
TTO values | 0.84 (0.79–0.89) | 0.84 (0.78–0.88) | 0.85 (0.80–0.89) | 0.690 |
EQ-5D VAS | 68 (50–77.5) | 65 (50–75) | 70 (50–80) | 0.717 |
↵* The ocular and oral symptoms were assessed according to the 2002 classification criteria.
↵† Altered oral test is defined as decreased unstimulated whole salivary flow (< 1.5 ml in 15 min) or salivary scintigraphy showing delayed uptake. pSS: primary Sjögren syndrome; KISS: Korean Initiative of primary Sjögren’s Syndrome; IQR: interquartile range; OSS: ocular stain score; SICCA: Sjögren’s International Collaborative Clinical Alliance; anti-Ro/SSA: anti-Ro/Sjögren syndrome A antibody; anti-La/SSB: anti-La/Sjögren syndrome B antibody; RF: rheumatoid factor; ANA: antinuclear antibodies; EULAR: European League Against Rheumatism; ESSDAI: EULAR Sjögren’s syndrome disease activity index; ESSPRI: EULAR Sjögren’s Syndrome Patient Reported Index; PtGA: patient’s global assessment; SSDDI: Sjögren’s Syndrome Disease Damage Index; TTO: time tradeoff; VAS: visual analog scales.